RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential

RBC Capital raised its price target for Cidara Therapeutics (CDTX) to $115 from $75, maintaining an Outperform rating, following positive Phase IIb NAVIGATE data for its CD388 flu prevention drug, which RBC now estimates could achieve $3.3 billion in peak worldwide sales. Despite shares tripling post-results, RBC sees a "significant valuation disconnect" and considerable upside, a sentiment echoed by Guggenheim which also raised its price target to $69. Concurrently, Cidara announced plans for a $250 million underwritten public offering to bolster its financial position and advance its therapeutic pipeline.

Analysis

Cidara Therapeutics (CDTX) is experiencing significant upward momentum driven by positive clinical trial results and subsequent bullish analyst revisions. The company announced statistically significant efficacy in its Phase 2b NAVIGATE trial for the CD388 flu prevention drug, a development Guggenheim termed 'critical validation.' This catalyst prompted RBC Capital to increase its price target to $115 from $75, projecting peak worldwide sales for the drug candidate could reach $3.3 billion. Despite the stock having already tripled following the trial results and posting a 440% gain over the past year, RBC's analysis suggests a 'significant valuation disconnect,' indicating that the current $1.35 billion market capitalization may not fully reflect the drug's long-term commercial potential. To fund future development, including Phase III trials, Cidara has announced a proposed $250 million underwritten public offering. While this capital raise is a strategic move to strengthen its financial position, it introduces potential dilution for existing shareholders and is coupled with RBC's 'Speculative Risk' designation, underscoring the high-risk, high-reward nature of the investment.

Key Decisions for Investors

• The positive Phase IIb data and significant analyst upgrades, including a $3.3 billion peak sales forecast from RBC, support a bullish outlook, suggesting the stock has further fundamental upside despite its recent surge.
• Investors should factor in the near-term dilutive impact of the planned $250 million public offering, which, while necessary to fund Phase III trials, could present a tactical entry point or cause short-term price pressure.
• Considering the stock's extreme volatility and the 'Speculative Risk' rating, positions should be managed carefully, acknowledging the binary risk associated with future clinical trial outcomes.